Multidisciplinary research and review journal | Online ISSN 3064-9870
REVIEWS   (Open Access)

Prevalence of Multi-drug Resistant (mdr) Pseudomonas sp. Among Patients Attending in Tertiary Care Hospital, Dhaka city, Bangladesh

S. M. Kamrul Islam 1,2, Maruf Abony 2, Aneeka Nawar Fatema 2, Suvamoy Datta 2*

+ Author Affiliations

Journal of Primeasia 1.3(1) 1-5 https://doi.org/10.25163/primeasia.11560011

Submitted: 29 September 2020  Revised: 07 November 2020  Published: 01 December 2020 

 

Unchecked antibiotic use is causing Pseudomonas sp. to become more resistant. It's crucial to manage antibiotics responsibly to combat this.

Abstract


The resistance pattern of Pseudomonas sp. isolates in recent years is increasing very rapidly because of the uncontrolled, unsupervised, and unnecessary usage of antibiotics. Current study aims to evaluate the prevalence of multidrug-resistant (MDR) Pseudomonas sp. isolated from clinical samples collected from tertiary care hospitals in Dhaka, Bangladesh. In this study, a total of 1440 samples were collected from January 2019 to September 2019, followed by using conventional methods, as well as the Kirby-Bauer disc diffusion method for culture and susceptibility of Samples, respectively. Finally, Stata 14 software was utilized to analyze the obtained data. From among 1440 samples, 480 (33.3%) cases were bacteriologically positive. Imipenem (11%) showed the least resistance followed by Meropenem (20%), where Nalidixic acid exhibited the highest drug resistance. Additionally, 202 (48.08%) and 278 (57.92%) cases were identified as MDR and non-drug-resistance (NDR). The number of male MDR cases was higher than females. It is alarming to increase MDR pathogens. This bacterial resistance can be prevented through control measures that limit the spread of resistant bacteria and the regular monitoring of this resistance phenotype of pathogens, along with the rational use of antimicrobial therapy.

Keywords: Multidrug-resistant (MDR), Pseudomonas sp., Kirby-Bauer disc diffusion, Tertiary care hospital, and Dhaka city.

References


Adeleye I, Adetosoye A 1993: Antimicrobial resistance patterns and plasmid survey of Salmonella and Shigella isolated in Ibadan, Nigeria. East African medical journal 70(5): 259-262.

Aguilera-Sáez J, Andreu-Solà V, Escartín NL, Garrido VR, Gil LA, García JS 2019: Extensively drug-resistant Pseudomonas aeruginosa outbreak in a burn unit: Management and solutions. Annals of Burns and Fire Disasters 32(1): 47.

Algammal AM, Mabrok M, Sivaramasamy E, Youssef FM, Atwa MH, El-Kholy AW, et al. 2020: Emerging MDR-Pseudomonas aeruginosa in fish commonly harbor oprL and toxA virulence genes and blaTEM, blaCTX-M, and tetA antibiotic-resistance genes. Scientific Reports 10(1): 1-12.

Anthony M, Rose B, Pegler MB, Elkins M, Service H, Thamotharampillai K, 2002: Genetic analysis of Pseudomonas aeruginosa isolates from the sputa of Australian adult cystic fibrosis patients. Journal of Clinical Microbiology 40(8): 2772-2778.

Asma R, Alam MJ, Rahimgir M, Asaduzzaman M, Islam AM, Uddin N, Khan MSI , Jahan N, Siddika SS, Datta S 2019: Prevalence of Multidrug-Resistant, Extensively Drug-Resistantand Pandrug-Resistant Uropathogens Isolated From UrinaryTract Infection Cases in Dhaka, Bangladesh. Avicenna Journal of Clinical Microbiology and Infection 6(2): 44-48.

Baban ST 2020: Molecular detection of carbapenemase-producing Pseudomonas aeruginosa isolated from intensive care units of surgical specialty hospital in Erbil city. Medical Journal of Babylon 17(2): 185.

Berrouane YF, McNutt L-A, Buschelman BJ, Rhomberg PR, Sanford MD, Hollis RJ, 2000: Outbreak of severe Pseudomonas aeruginosa infections caused by a contaminated drain in a whirlpool bathtub. Clinical infectious diseases 31(6): 1331-1337.

Bhuiya M, Sarkar MK, Sohag MH, Ali H, Roy CK, Akther L. 2018: Enumerating antibiotic susceptibility patterns of Pseudomonas aeruginosa isolated from different sources in Dhaka City. The open microbiology journal 12: 172.

Bronzwaer SL, Cars O, Buchholz U, Mölstad S, Goettsch W, Veldhuijzen IK. 2002: The relationship between antimicrobial use and antimicrobial resistance in Europe. Emerging infectious diseases 8(3): 278.

Brun-Buisson C, Philippon A, Ansquer M, Legrand P, Montravers F, Duval J 1987: Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. The Lancet 330(8554): 302-306.

Carmeli Y, Troillet N, Karchmer AW, Samore MH 1999: Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Archives of Internal Medicine 159(10): 1127-1132.

Chaoui L, Mhand R, Mellouki F, Rhallabi N 2019: Contamination of the surfaces of a health care environment by multidrug-resistant (MDR) bacteria. International journal of microbiology 2019.

Clinical and Laboratory Standards Institute (CLSI) 2013: Performance standard for antimicrobial suspectibility testing. 23rd International Supplement Document 33 : 1-199.

Devi LS, Broor S, Rautela RS, Grover SS, Chakravarti A, Chattopadhya D 2020: Increasing prevalence of Escherichia coli and Klebsiella pneumoniae producing CTX-M-type extended-spectrum beta-lactamase, carbapenemase, and NDM-1 in patients from a rural community with community acquired infections: A 3-year study. International Journal of Applied and Basic Medical Research 10(3): 156.

Dimopoulos G, Akova M, Rello J, Poulakou G 2020: Understanding resistance in Pseudomonas. Intensive care medicine 46(2): 350-352.

Gales A, Jones R, Turnidge J, Rennie R, Ramphal R 2001: Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. Clinical infectious diseases 32(2): 146-155.

Hauser AR, Cobb E, Bodí M, Mariscal D, Vallés J, Engel JN, et al. 2002: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Critical care medicine 30(3): 521-528.

Jameson JL, Kasper DL, Fauci AS, Hauser SL, Longo DL, Loscalzo J 2018: Harrison's principles of internal medicine. McGraw-hill education. New York

Kato K, Iwai S, Kumasaka K, Horikoshi A, Inada S, Inamatsu T 2001: Survey of antibiotic resistance in Pseudomonas aeruginosa by the Tokyo Johoku Association of Pseudomonas Studies. Journal of infection and chemotherapy 7(4): 258-262.

Khan H, Bari F, Masood A, Ghani F, Khan Z, Khan WY 2020: Phenotypic Detection of Extended Spectrum Beta-Lactamases in Uro-pathogens. An Experience from Qazi Hussain Ahmed Medical Complex, Nowshera. Journal of Rawalpindi Medical College 24(1): 40-45.

Kugelberg E, Löfmark S, Wretlind B, Andersson DI 2005: Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 55(1): 22-30.

Kutty N 2011: Treating children without antibiotics in primary healthcare. Oman Medical Journal 100(325): 1-3

Lai C-C, Chen C-C, Lu Y-C, Lin T-P, Chuang Y-C, Tang H-J 2018: Appropriate composites of cefoperazone–sulbactam against multidrug-resistant organisms. Infection and Drug Resistance 11: 1441.

Law N, Logan C, Yung G, Furr C-LL, Lehman SM, Morales S, et al. 2019: Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection 47(4): 665-668.

Liao S, Zhang Y, Pan X, Zhu F, Jiang C, Liu Q, et al. 2019: Antibacterial activity and mechanism of silver nanoparticles against multidrug-resistant Pseudomonas aeruginosa. International journal of nanomedicine 14: 1469.

Lister PD, Wolter DJ, Hanson ND 2009: Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical microbiology reviews 22(4): 582-610.

Moradali MF, Ghods S, Rehm BH 2017: Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence. Frontiers in cellular and infection microbiology 7: 39.

Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V 2014: Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrobial resistance and infection control 3(1): 1-16.

National Nosocomial Infections Surveillance (NNIS) System Report 2004: National Nosocomial Infection Surveillance from January 1992 through June 2004. American Journal of Infection Control 32: 470-485.

Paghdar D, Nayak J, Mathakiya R, Parmar B, Gida H, Bhavsar P 2020: Isolation and Molecular Characterization of Extended Spectrum Beta Lactamase Producing Escherichia coli from Milk. Journal of Animal Research 10(1): 143-148.

Palavutitotai N, Jitmuang A, Tongsai S, Kiratisin P, Angkasekwinai N 2018: Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections. Plos one 13(2): 1-13.

Ray CG, Ryan KJ 2010: Sherris medical microbiology. 6th ed, McGraw-Hill. New York

Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J. 2001: Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. The Journal of infectious diseases 183(12): 1767-1774.

Seppänen L, Lauhio A, Lindqvist C, Suuronen R, Rautemaa R 2008: Analysis of systemic and local odontogenic infection complications requiring hospital care. Journal of Infection 57(2): 116-122.

Shi Q, Huang C, Xiao T, Wu Z, Xiao Y 2019: A retrospective analysis of Pseudomonas aeruginosa bloodstream infections: prevalence, risk factors, and outcome in carbapenem-susceptible and-non-susceptible infections. Antimicrobial Resistance & Infection Control 8(1): 1-9.

Tang SY, Zhang SW, Wu JD, Wu F, Zhang J, Dong JT 2018: Comparison of mono-and combination antibiotic therapy for the treatment of Pseudomonas aeruginosa bacteraemia: A cumulative meta-analysis of cohort studies. Experimental and therapeutic medicine 15(3): 2418-2428.

Tkhilaishvili T, Winkler T, Müller M, Perka C, Trampuz A 2019: Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 64(1): e00924-00919.

Uddin ME, Akter T, Sultana P, Hasan MI, Lubna MA, Al Monem H 2018: Isolation, identification and antimicrobial susceptibility profile analysis of Vibrio cholerae O1 from stool samples of Bangladesh. Advances in Microbiology 8(3): 188-196.

Vandewoude KH, Blot SI, Hoste EA 2000: Antibiotic resistance and exposure to different generation cephalosporins. Critical care medicine 28(7): 2678

Weinstein RA, Gaynes R, Edwards JR, System NNIS 2005: Overview of nosocomial infections caused by gram-negative bacilli. Clinical infectious diseases 41(6): 848-854.

Full Text
Export Citation

View Dimensions


View Plumx



View Altmetric



0
Save
0
Citation
454
View
0
Share